PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS
OBJECTIVES: I. Assess the toxic effects of intracystic administration of iodine-131-labeled
anti-tenascin monoclonal antibody 81C6. II. Identify any objective therapeutic responses to
this treatment in patients with recurrent cystic anaplastic gliomas.
OUTLINE: Radioimmunotherapy. Iodine-131-Labeled Anti-Tenascin Monoclonal Antibody 81C6,
131I-81C6.
PROJECTED ACCRUAL: Three to six patients will be entered at each dose studied.
Interventional
Primary Purpose: Treatment
Darell D. Bigner, MD, PhD
Study Chair
Duke Cancer Institute
United States: Federal Government
CDR0000064689
NCT00002753
November 1991
April 2001
Name | Location |
---|---|
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |